Final results of the ACTS-CC 02 trial: A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer.

Naohiro Tomita,Shin Sasaki,Tetsuya Kusumoto,Jun Watanabe,Yoshiyuki Sakamoto,Kazuhiro Yoshida,Atsuyuki Maeda,Jin Teshima,Mitsuru Yokota,Chihiro Tanaka,Junichiro Yamauchi,Hiroyuki Uetake,Michio Itabashi,Keiichi Takahashi,Hideo Baba,Kenjiro Kotake,Narikazu Boku,Keisuke Aiba,Satoshi Morita,Kenichi Sugihara

Final results of the ACTS-CC 02 trial: A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer.

2021

59Background: As previously reported (Sunami E, et al. Clin Colorectal Cancer. 2020), the ACTS-CC 02 trial demonstrated that S-1 and oxaliplatin (SOX) was not superior to UFT/leucovorin (LV) in ter...

Keywords:

Oncology
Internal medicine
Medicine
Oxaliplatin
Colorectal cancer
Stage III Colon Cancer
adjuvant chemotherapy
UFT/Leucovorin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations